Jiangsu Sihuan Bioengineering Co., Ltd's high P/S ratio is alarming due to its recent sluggish growth. If the current medium-term revenue trends persist, it could severely affect the share price. The company's trading position is deemed risky due to falling revenues and high P/S ratio.

The 11% compound share price fall over three years is justified by fundamental deterioration. Uncertainty looms over future profitability without more cash. Last year's performance indicates unresolved challenges, worse than the annualised loss of 0.3% over the last half decade. Investors should heed 2 warning signs.

The high P/S ratio at Jiangsu Sihuan Bioengineering, despite falling revenue and unsatisfactory medium-term growth, is a concern. Unless there's a significant medium-term turnaround, the stock might be overvalued, risking investor disappointment.